Biogen details 2026 shareholder voting results

Biogen Inc. reported the voting results from its 2026 Annual Meeting of Stockholders held on June 9, 2026.

Accepted by SEC EDGAR 06/10/2026 - 04:54 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Biogen Inc. reported the voting results from its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders voted on the election of directors and other proposals. Director nominees, including Christopher A. Viehbacher and Lloyd Minor, each received substantially more votes "For" than "Against," with notable support such as 121,127,966 votes "For" for Mr. Viehbacher and 121,220,738 votes "For" for Dr. Minor. One proposal received 124,551,887 votes "For" versus 6,627,086 "Against," while another proposal received 114,184,816 votes "For" and 7,454,737 "Against," along with broker non-votes.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for Lloyd Minor: 121,220,738 votes Votes for Christopher A. Viehbacher: 121,127,966 votes Proposal vote – For: 124,551,887 votes +2 more

5 metrics

Votes for Lloyd Minor 121,220,738 votes Director election at 2026 Annual Meeting

Votes for Christopher A. Viehbacher 121,127,966 votes Director election at 2026 Annual Meeting

Proposal vote – For 124,551,887 votes One meeting proposal with 6,627,086 Against and 87,576 abstentions

Proposal vote – For with broker non-votes 114,184,816 votes Another proposal with 7,454,737 Against, 267,869 abstentions, 9,359,127 broker non-votes

Broker non-votes on proposal 9,359,127 shares Recorded on a proposal at the 2026 Annual Meeting

Key Terms

Annual Meeting of Stockholders, Broker Non-Votes, Emerging growth company

3 terms

Annual Meeting of Stockholders financial

"On June 9, 2026, Biogen Inc. held its 2026 Annual Meeting of Stockholders."

Broker Non-Votes financial

"Broker Non-Votes 9,359,127"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

Emerging growth company regulatory

"Emerging growth company On June 9, 2026, Biogen Inc."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Biogen (BIIB) disclose in its latest 8-K filing?

Biogen disclosed the final voting results from its 2026 Annual Meeting of Stockholders. The filing details how shareholders voted on director elections and other proposals, including specific "For," "Against," "Abstain," and broker non-vote tallies for each item.

How did Biogen (BIIB) shareholders vote on director nominees in 2026?

Biogen shareholders gave strong support to all listed director nominees, with each receiving more votes "For" than "Against." For example, Christopher A. Viehbacher received 121,127,966 votes "For" and 688,051 "Against," while Lloyd Minor received 121,220,738 "For" and 594,000 "Against."

What were the total vote counts on one key Biogen (BIIB) proposal?

One proposal at Biogen’s 2026 Annual Meeting received 124,551,887 votes "For," 6,627,086 votes "Against," and 87,576 abstentions. These figures show a significantly higher number of affirmative votes than opposing votes among shares present and entitled to vote.

Did any Biogen (BIIB) proposal include broker non-votes in 2026?

Yes. One proposal recorded 114,184,816 votes "For," 7,454,737 "Against," 267,869 abstentions, and 9,359,127 broker non-votes. Broker non-votes generally arise when intermediaries lack discretion to vote uninstructed shares on certain matters presented to shareholders.

Where was Biogen’s 2026 Annual Meeting information recorded?

The 2026 Annual Meeting voting results were recorded in a current report on Form 8-K. This report lists director nominees, their respective vote totals, and the vote counts for other proposals considered by Biogen stockholders at the meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2026

Biogen Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-19311	33-0112644
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

225 Binney Street, Cambridge, Massachusetts 02142

(Address of principal executive offices; Zip Code)

Registrant’s telephone number, including area code: (617) 679-2000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0005 par value per share	BIIB	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

¨ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07

Submission of Matters to a Vote of Security Holders

On June 9, 2026, Biogen Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders. The final voting results for this meeting are as follows:

Stockholders elected ten nominees to the Board of Directors to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows:

Nominee	Votes For	Votes Against	Abstentions	Broker Non-Votes
Maria C. Freire	103,033,121	18,790,237	84,064	9,359,127
William A. Hawkins	102,135,204	19,683,098	89,120	9,359,127
Susan K. Langer	103,931,406	17,886,544	89,472	9,359,127
Jesus B. Mantas	101,698,187	20,117,077	92,158	9,359,127
Lloyd Minor	121,220,738	594,000	92,684	9,359,127
Menelas Pangalos	121,130,060	682,983	94,379	9,359,127
Monish Patolawala	120,796,249	1,016,057	95,116	9,359,127
Eric K. Rowinsky	93,569,685	28,216,589	121,148	9,359,127
Stephen A. Sherwin	103,025,923	18,788,272	93,227	9,359,127
Christopher A. Viehbacher	121,127,966	688,051	91,405	9,359,127

Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows:

Votes For		Votes Against		Abstentions
124,551,887		6,627,086		87,576

Stockholders approved the advisory vote on executive compensation, with the votes cast as follows:

Votes For		Votes Against		Abstentions		Broker Non-Votes
114,184,816		7,454,737		267,869		9,359,127

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Biogen Inc.


	By:	/s/ Wendell Taylor
		Wendell Taylor
		Secretary
Date: June 10, 2026

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents